Obagi Medical and VIO Med Spa Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ(TM)
MWN-AI** Summary
Obagi Medical has partnered with VIO Med Spa to launch the Aesthetics Leadership with Obagi’s Hyaluronic Acid (ALOHA) Program, aiming to gather real-world evidence on the performance of Obagi® saypha® MagIQ™. This collaboration is significant as it capitalizes on VIO Med Spa's rapid growth and commitment to advanced aesthetic treatments, emphasizing quality care across its expanding network.
The ALOHA Program is designed to evaluate both the clinical outcomes of the Obagi filler and overall patient experiences in a structured multi-site assessment. VIO Med Spa will harness its expertise in injectables and patient education to generate valuable insights about the product's efficacy in high-volume settings. Dr. Alan Durkin, Chief Medical Officer of VIO Med Spa, highlighted the alignment of the ALOHA Program with their mission, which focuses on integrating skincare and injectable protocols to elevate aesthetic medicine.
The program aims to standardize data collection across all participating locations, starting with immersive training at the upcoming VIO University. This initiative allows practitioners to deliver comprehensive Obagi protocols, enhancing patient satisfaction and fostering long-lasting provider-patient relationships.
Drew Fine, U.S. General Manager for the Professional Channel at Obagi, stated that partnering with a prominent entity like VIO Med Spa underscores Obagi's commitment to launching evidence-backed aesthetic solutions. Obagi® saypha® MagIQ™, featuring proprietary MACRO Core Technology, promises natural-looking results with leading performance qualities.
Obagi Medical, an industry trailblazer in skincare, has been addressing various skin concerns for over 35 years, while VIO Med Spa is recognized for its full-service aesthetic offerings. This collaboration not only reinforces their joint commitment to clinical excellence but also seeks to drive innovation in the evolving med spa industry.
MWN-AI** Analysis
The recent partnership between Obagi Medical and VIO Med Spa through the Aesthetics Leadership with Obagi’s Hyaluronic Acid (ALOHA) Program marks a significant development worth monitoring for investors focused on the aesthetic and skincare sectors. Obagi Medical, recognized for its innovation in physician-dispensed skincare, is poised to leverage VIO Med Spa's rapid growth and extensive network as they initiate a structured assessment of the Obagi® saypha® MagIQ™, a product that boasts proprietary MACRO Core Technology for enhanced performance.
From a market perspective, this collaboration enhances Obagi’s ability to generate verified real-world evidence that can substantiate the product’s efficacy and safety, a crucial factor in today’s competitive aesthetic market. By gathering standardized data across multiple sites, the ALOHA Program aims not just to improve the product's market positioning but also to solidify Obagi Medical's reputation as a leader in evidence-based aesthetic solutions.
Moreover, the strong focus on patient outcomes and satisfaction aligns well with industry trends that favor personalized skincare solutions, suggesting a wider appetite for Obagi Medical's offerings. As VIO Med Spa focuses on integrating skincare with injectables, Obagi stands to benefit from cross-promotion opportunities.
Investors looking at Obagi Medical through Waldencast plc (NASDAQ: WALD) may find this partnership a compelling reason to adopt a bullish outlook. Given the growing demand for advanced aesthetic treatments, and the anticipated data-driven insights from this collaboration, Obagi is well-positioned to capture market share and potentially drive revenue growth in the upcoming quarters.
In conclusion, proactive monitoring of the ALOHA Program's outcomes will be key for investors. Successful execution could not only validate Obagi's innovations but also fortify Waldencast's standing in the evolving wellness sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
NEW YORK and STRONGSVILLE, Ohio, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), today announced VIO Med Spa as a launch partner for the Aesthetics Leadership with Obagi’s Hyaluronic Acid (ALOHA) Program. VIO Med Spa was selected for its rapid growth, expert-led approach to advanced aesthetic treatments, and dedication to delivering high-quality, results-driven care across its expanding national network of locations.
Through this real-world evaluation collaboration, VIO Med Spa will conduct a structured, multi-site assessment of Obagi® saypha® MagIQ™ across its practices. The program will leverage VIO Med Spa’s strengths in innovative injectables, personalized wellness protocols, and patient-focused education to generate robust real-world evidence on the filler’s performance in diverse, high-volume aesthetic environments.
“At VIO Med Spa, we’re committed to elevating aesthetic medicine through clinical excellence, innovation, and exceptional patient outcomes,” said Dr. Alan Durkin, Chief Medical Officer of VIO Med Spa. “Obagi’s ALOHA Program perfectly aligns with our mission by emphasizing real-world data and integrated skincare-injectable protocols. This partnership allows us to contribute meaningful insights that enhance results for our patients and advance the industry as a whole.”
The ALOHA Program evaluates both clinical performance and patient experience while providing providers with comprehensive Obagi protocols to boost satisfaction, build lasting relationships, and achieve consistent, high-quality outcomes. Standardized data will be collected across participating VIO Med Spa locations. The program kicks off at the upcoming VIO University program which includes 2 days of immersive expert led training for the VIO network of practices.
“Partnering with a dynamic, growth-oriented leader like VIO Med Spa reinforces Obagi’s commitment to launching aesthetics solutions grounded in authentic, practice-based evidence,” said Drew Fine, U.S. General Manager, Professional Channel. “The ALOHA collaboration with VIO Med Spa brings together clinical expertise, operational scale, and a shared passion for transformative patient care across the evolving med spa landscape.”
Obagi® saypha® MagIQ™, developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology to create a stable three-dimensional hyaluronic acid matrix. The technology is designed to deliver natural-looking results with category-leading performance, including high usable HA content upon injection, consistent gel distribution, and a predictable injection force and swelling profile¹.
For more information about ALOHA, visit https://obagi-professional.com.
About Obagi Medical
Obagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, with a legacy of 35+ years of experience. Initially known for its leadership in the treatment of hyperpigmentation with the Obagi Nu-Derm® System, Obagi Medical products are designed to address a variety of skin concerns, including premature aging, photodamage, skin discoloration, acne, and sun damage. As the fastest-growing professional skincare brand in the U.S. in 2024,² Obagi Medical empowers individuals to achieve healthy, beautiful skin. More information about Obagi Medical is available on the brand's website, https://www.obagi.com.
About VIO Med Spa
VIO Med Spa is a nationally recognized, award-winning franchise of full-service medical spas specializing in advanced aesthetic and wellness treatments, including injectables, skin rejuvenation, body contouring, facials, and more. With dozens of locations nationwide and a focus on clinical excellence and patient safety, VIO Med Spa delivers innovative, results-oriented care led by expert providers. For more information, visit www.viomedspa.com.
About Waldencast plc
Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand’s distinct DNA. For more information please visit: https://ir.waldencast.com.
Media Contact:
obagi@behrmancesa.com
Source: Waldencast plc
¹ Puljic A, Frank K, Cohen J, Otto K, Mayr J, Hugh-Bloch A, Kuroki-Hasenöhrl, D. A Scientific Framework for Comparing Hyaluronic Acid Filler Crosslinking Technologies. Gels. 2025; 11(7):487
² Among the Top 10 Professional Skin Care Brands in the U.S., According to Kline’s 2024 Global Professional Skin Care Series (China, Europe and the U.S.)
FAQ**
How does Waldencast Acquisition Corp. WALD plan to leverage the partnership with VIO Med Spa to enhance its position in the skincare and aesthetic solutions market in New York?
What are the anticipated economic impacts of the collaboration between Waldencast Acquisition Corp. WALD and VIO Med Spa on the med spa industry in Strongsville, Ohio?
In what ways does the ALOHA Program initiated by Waldencast Acquisition Corp. WALD aim to improve patient outcomes and satisfaction, particularly in an urban market like New York vs. a suburban market like Strongsville, Ohio?
How will the multi-site assessment of Obagi® saypha® MagIQ™ contribute to Waldencast Acquisition Corp. WALD's strategy for growth in both New York and Strongsville, Ohio?
**MWN-AI FAQ is based on asking OpenAI questions about Waldencast Acquisition Corp. (NASDAQ: WALD).
NASDAQ: WALD
WALD Trading
-4.69% G/L:
$1.525 Last:
13,064 Volume:
$1.51 Open:
